Cross Talk between Estradiol and mTOR Kinase in the Regulation of Ovarian Granulosa Proliferation

Reproductive Sciences

Volumn 19, Issue 2, 2012, Pages 143-151

  Yu, James ^a   Thomson, Travis C ^b   Johnson, Joshua ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

estradiol; follicle growth; folliculogenesis; mTOR; ovary

Indexed keywords

BETA1 INTEGRIN; CALCINEURIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; ESTRADIOL; EVEROLIMUS; INHIBIN A; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P16; PROTEIN P70; TEMSIROLIMUS;

ANAPHASE; ANIMAL CELL; ARTICLE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENETIC TRANSCRIPTION; GRANULOSA CELL; GROWTH INHIBITION; MOLECULAR INTERACTION; NONHUMAN; OVARY FOLLICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; ESTRADIOL; FEMALE; GRANULOSA CELLS; RATS; RECEPTORS, ESTRADIOL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84859914883     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111424447     Document Type: Article

References (42)

1. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122-1128. (Pubitemid 39468014)
2. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res. 1995;1:53-71.
3. Wullschleger S, Loewith R, Hall MN. Tor signaling in growth and metabolism. Cell. 2006;124(3):471-484. (Pubitemid 43199434)
4. Kirchner G, Meier-Wiedenbach I, Manns M. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83-95. (Pubitemid 38283132)
5. Pangas SA. Growth factors in ovarian development. Semin Reprod Med. 2007;25(4):225-234. (Pubitemid 47047906)
6. Sato E, Kimura N, Yokoo M, Miyake Y, Ikeda JE. Morphodynamics of ovarian follicles during oogenesis in mice. Microsc Res Tech. 2006;69(6):427-435. (Pubitemid 43878053)
7. Alam H, Maizels E, Park Y, et al. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 2004;279:19431-19440. (Pubitemid 38623376)
8. Kayampilly PP, Menon KM. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of rapamycin signaling through an extracellular signal-regulated kinase-dependent pathway in rat granulosa cells. Endocrinology 2007;148:3950-3957. (Pubitemid 47105853)
9. Ponticelli C. The pleiotropic effects of mTor inhibitors. J Nephrol. 2004;17(6):762-768. (Pubitemid 41158294)
10. Song J, Salek-Ardakani S, So T, Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol. 2007;8(1):64-73. (Pubitemid 46242360)
11. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J. mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS ONE. 2011;6, 7:e21415.
12. Yaba A, Bianchi V, Borini A, Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod Sci. 2008;15(2):128-138. (Pubitemid 351903539)
13. Stewnius Y, Gorunova L, Jonson T, et al. Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci U S A. 2005;102(15):5541-5546. (Pubitemid 40530294)
14. Stein L, Stoica G, Tilley R, Burghardt R. Rat ovarian granulosa cell culture: a model system for the study of cell-cell communication during multistep transformation. Cancer Res. 1991;51(2):696-706.
15. Akcakanat A, Singh G, Hung M, Meric-Bernstam F. Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007;362(2):330-333. (Pubitemid 47332412)
16. Barilli A, Visigalli R, Sala R, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res. 2008;78(3):563-571. (Pubitemid 351769758)
17. Sarbassov D, Ali S, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159-168.
18. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807-826. (Pubitemid 32295062)
19. Dmitriev S, Terenin I, Dunaevsky Y, Merrick W, Shatsky I. Assembly of 48S translation initiation complexes from purified components with mRNAs that have some base pairing within their 5′ untranslated regions. Mol Cell Biol. 2003;23(24):8925-8933. (Pubitemid 37499783)
20. Rousseau D, Gingras A, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene. 1996;13(11):2415-2420. (Pubitemid 27026024)
21. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst. 2001;93(20):1517-1519. (Pubitemid 32998477)
22. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36-42. (Pubitemid 27327197)
23. Atkins M, Hidalgo M, Stadler W, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909-918. (Pubitemid 41103603)
24. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009;26(1):55-67.
25. Telfer E, McLaughlin M, Ding C, Thong K. A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod. 2008;23(5):1151-1158. (Pubitemid 351757334)
26. Xu M, Kreeger PK, Shea LD, Woodruff TK. Tissue-engineered follicles produce live, fertile offspring. Tissue Eng. 2006;12(10):2739-2746. (Pubitemid 46141242)
27. Eppig J, Pendola F, Wigglesworth K, Pendola J. Mouse oocytes regulate metabolic cooperativity between granulosa cells and oocytes: amino acid transport. Biol Reprod. 2005;73(2):351-357. (Pubitemid 41022795)
28. Eppig J, Wigglesworth K, Pendola F. The mammalian oocyte orchestrates the rate of ovarian follicular development. Proc Natl Acad Sci U S A. 2002;99(5):2890-2894. (Pubitemid 34240556)
29. Matzuk M, Burns K, Viveiros M, Eppig J. Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science. 2002;296(5576):2178-2180. (Pubitemid 34680291)
30. Cameron JL. Stress and behaviorally induced reproductive dysfunction in primates. Semin Reprod Endocrinol. 1997;15(1):37-45. (Pubitemid 27113781)
31. Schenker JG, Meirow D, Schenker E. Stress and human reproduction. Eur J Obstet Gynecol Reprod Biol. 1992;45(1):1-8.
32. Szoltys M, Sakiewicz A, Galas J, Jaworska-Caudelier M, Kula E. Changes in follicular fluid concentrations of steroids, the pattern of steroid secretion and aromatization capability of incubated preovulatory follicular wall of rats. Reprod Biol. 2001;1(1):42-50.
33. Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R, Mor G. Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med. 2003;13(1):39-44. (Pubitemid 36216533)
34. Straszewski-Chavez S, Abrahams V, Funai E, Mor G. X-linked inhibitor of apoptosis (XIAP) confers human trophoblast cell resistance to Fas-mediated apoptosis. Mol Hum Reprod. 2004;10(1):33-41. (Pubitemid 38195963)
35. Walters K, Binnie J, Campbell B, Armstrong D, Telfer E. The effects of IGF-I on bovine follicle development and IGFBP-2 expression are dose and stage dependent. Reproduction. 2006;131(3):515-523.
36. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11(14):5319-5328. (Pubitemid 41003721)
37. Chang S, Miron P, Miron A, Iglehart J. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res. 2007;138(1):37-44. (Pubitemid 46227456)
38. Santen R, Song R, Masamura S, et al. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol. 2008;630:19-34.
39. Yin X, Wang G, Khan-Dawood F. Requirements of phosphatidylinositol-3 kinase and mammalian target of rapamycin for estrogen-induced proliferation in uterine leiomyoma- and myometrium-derived cell lines. Am J Obstet Gynecol. 2007;196(2):1-5.
40. Gisselsson D. Classification of chromosome segregation errors in cancer. Chromosoma. 2008;117(6):511-519.
41. Temime-Smaali N, Guittat L, Wenner T, et al. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres. EMBO J. 2008;27(10):1513-1524. (Pubitemid 351733329)
42. Chan K, North P, Hickson I. BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J. 2007;26(14):3397-3409. (Pubitemid 47123542)